Immune checkpoint inhibitor myocarditis: a systematic case study

Immune checkpoint inhibitor myocarditis: a systematic case study

Myocarditis is a life-threatening complication of immune checkpoint inhibitor therapy. Over the past ten years, drugs in this group have been used in the treatment of a wide range of hematological diseases and solid tumors. With steadily growing life expectancy of cancer patients, problems associate...

Full description

Bibliographic Details
Main Authors:	E. A. Kushnareva, O. M. Moiseeva
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2020-12-01
Series:	Российский кардиологический журнал
Subjects:	checkpoint inhibitors myocarditis cardiotoxicity
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/3910

Similar Items

Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis
by: Yunwei LIU, et al.
Published: (2021-09-01)

Myocarditis associated with immune checkpoint inhibitors: Practical considerations in diagnosis and management
by: Muhammet Gürdoğan, et al.
Published: (2020-07-01)

Clinical manifestation and management of immune checkpoint inhibitor‐associated cardiotoxicity
by: Xiaoxiao Guo, et al.
Published: (2020-02-01)

Cardiovascular complications of immune checkpoint inhibitors
by: A. A. Kulievа, et al.
Published: (2020-04-01)

Role of Cardiac Imaging in the Diagnosis of Immune Checkpoints Inhibitors Related Myocarditis
by: Stéphane Ederhy, et al.
Published: (2021-05-01)

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature
by: Nikhil Agrawal, et al.
Published: (2019-03-01)

Smoldering myocarditis following immune checkpoint blockade
by: Timothy G. Norwood, et al.
Published: (2017-11-01)

A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors
by: Jessica Castrillon Lal, et al.
Published: (2021-05-01)

Fulminant myocarditis induced by immune checkpoint inhibitor nivolumab: a case report and review of the literature
by: Feifei Wang, et al.
Published: (2021-07-01)

Late-Onset Giant Cell Myocarditis Due to Enterovirus During Treatment With Immune Checkpoint Inhibitors
by: Mariana Mirabel, MD, PhD, et al.
Published: (2020-09-01)

Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case series
by: Robert S. Zhang, et al.
Published: (2021-03-01)

How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor Therapy
by: Paolo Spallarossa, et al.
Published: (2020-06-01)

An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors
by: Roberta Esposito, et al.
Published: (2021-05-01)

Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems
by: Rulan Ma, et al.
Published: (2021-01-01)

Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review
by: Grzegorz Sławiński, et al.
Published: (2020-09-01)

Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases
by: Emma Matzen, et al.
Published: (2021-08-01)

Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy
by: Whitney Barham, et al.
Published: (2021-02-01)

Early Detection of Checkpoint Inhibitor-Associated Myocarditis Using 68Ga-FAPI PET/CT
by: Daniel Finke, et al.
Published: (2021-02-01)

Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management
by: Yu-Wen Zhou, et al.
Published: (2019-11-01)

Immune Checkpoint Inhibitors Mediated Lymphocytic and Giant Cell Myocarditis: Uncovering Etiological Mechanisms
by: Rishi Rikhi, et al.
Published: (2021-08-01)

Keeping immune checkpoint inhibitor myocarditis in check: advanced circulatory mechanical support as a bridge to recovery
by: Ashley F. Stein‐Merlob, et al.
Published: (2021-10-01)

Immune Checkpoint Inhibitor–Related Cardiovascular Toxicity in Lung Cancer
by: Lova Sun, MD, et al.
Published: (2019-12-01)

Myocardial and Pericardial Toxicity Associated With Immune Checkpoint Inhibitors in Cancer Patients
by: Johnny Chahine, MD, et al.
Published: (2020-02-01)

Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock
by: Osnat Itzhaki Ben Zadok, MD, MS, et al.
Published: (2019-09-01)

A systematic review of myasthenia gravis complicated with myocarditis
by: Wei Cheng, et al.
Published: (2021-08-01)

Gender differences in cardiotoxicities associated with immune checkpoint inhibitor therapy in cancer patients
by: Sheharyar Minhas, et al.
Published: (2020-01-01)

Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology
by: Dong-Yi Chen, et al.
Published: (2020-10-01)

Immune Checkpoint Inhibitors and the Heart
by: Diana Larisa Mocan-Hognogi, et al.
Published: (2021-09-01)

Pre-Existing Cardiovascular Conditions as Clinical Predictors of Myocarditis Reporting with Immune Checkpoint Inhibitors: A VigiBase Study
by: Roberta Noseda, et al.
Published: (2020-11-01)

Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer
by: Kalyan R. Chitturi, DO, et al.
Published: (2019-12-01)

Cardiac Complications in Immune Checkpoint Inhibition Therapy
by: Kazuko Tajiri, et al.
Published: (2019-01-01)

Inflammatory Biomarkers to Detect Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Lung Cancer Patients
by: Mandar A. Aras, MD, PhD, et al.
Published: (2020-09-01)

Clinical Diagnosis and Treatment Recommendations for Cardiac Adverse Reactions Related to Immune Checkpoint Inhibitor
by: Xiaoxiao GUO, et al.
Published: (2019-10-01)

Characterization of Immune Checkpoint Inhibitor-Related Cardiotoxicity in Lung Cancer Patients From a Rural Setting
by: Melissa Y.Y. Moey, MD, MSc, et al.
Published: (2020-09-01)

Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors
by: YU Lin, et al.
Published: (2021-08-01)

Immune Checkpoint Inhibitor-Associated Myocarditis
by: Grigorios Chatzantonis, MD, et al.
Published: (2020-04-01)

Associated Myocarditis: A Predictive Factor for Response?
by: Walid Shalata, et al.
Published: (2020-05-01)

Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS
by: Chenxin Chen, et al.
Published: (2021-02-01)

Myocarditis in 2020
by: Tahir S. Kafil, MD, et al.
Published: (2020-02-01)

Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report
by: Jason Cham, et al.
Published: (2021-05-01)

Cannot write session to /tmp/vufind_sessions/sess_hq233uuebp4qr8cnlishkn8hag